-
MDM1, p53, and Chemoradiotherapy in Colorectal Cancer
2026-10-05
Ren et al. identify MDM1 as a potential biomarker and mechanistic regulator of chemoradiotherapy sensitivity in colorectal cancer, linking MDM1 expression to YBX1–TP53 regulation and apoptosis. The findings support further biomarker validation but remain primarily preclinical and do not establish a clinical treatment strategy.
-
Endothelial STING–JAK1 Signaling in Tumor Immunity
2026-10-04
The 2025 JCI study identifies endothelial STING as a critical determinant of STING agonist–induced vessel normalization and CD8+ T cell infiltration. Its central mechanistic contribution is the finding that, in endothelial cells, STING can act downstream of IFNAR to promote JAK1–STAT signaling through a palmitoylation-dependent interaction rather than functioning only as the canonical upstream adaptor for interferon induction.
-
Baricitinib and the Evidence Architecture of PSC
2026-10-03
Baricitinib (LY3009104) offers a selective pharmacological lens for interpreting JAK-STAT activity in primary sclerosing cholangitis. This article distinguishes spatial association from causal evidence and explains how PD-L1–IL-6 findings can be evaluated without overextending mechanistic or therapeutic conclusions.
-
Tacrine hydrochloride hydrate: Research Workflows
2026-10-02
Build reproducible cholinesterase, cholinergic signaling, and neuroprotection workflows with Tacrine hydrochloride hydrate, also known as Tetrahydroaminacrine. The guide connects enzyme inhibition data with cell-based Alzheimer’s disease research while emphasizing solvent control, exposure limits, and hepatotoxicity-aware interpretation.
-
CERES-XIAN Links dsRNA to Mitochondrial ROS
2026-10-01
A 2026 The Plant Journal study identifies the plant-specific AtCERES–AtXIAN axis as a positive regulator of double-stranded RNA-triggered immunity in Arabidopsis. Its central advance is to place mitochondrial reactive oxygen species upstream of defense-gene activation, MPK3/6 phosphorylation, and seedling growth inhibition, independently of the canonical RBOHD oxidative burst.
-
4-MUG Workflows for Lysosomal Enzyme Assays
2026-10-01
Turn β-glucosidase and β-glucocerebrosidase activity into a sensitive 4-methylumbelliferone fluorescence readout with 4-MUG. This practical guide connects plate-based assay design, Gaucher disease models, and GBA1 mRNA rescue studies while emphasizing calibration, pH control, and troubleshooting.
-
Prednisolone (B2012) for Reliable Cell Assays
2026-09-30
This scenario-based guide explains how Prednisolone (SKU B2012), a high-purity synthetic glucocorticoid, can support better-controlled viability, proliferation, and cytotoxicity experiments. It covers receptor biology, solvent compatibility, stock preparation, data interpretation, and practical supplier selection without confusing glucocorticoid signaling with ERAD-based protein degradation.
-
Cy3 NHS ester (non-sulfonated) Workflow Guide
2026-09-30
This guide explains how Cy3 NHS ester (non-sulfonated), SKU A8100, can be used for covalent fluorescent labeling of amino-containing proteins, peptides, and oligonucleotides. It is appropriate when DMSO, DMF, or another organic co-solvent is acceptable, but it is not the preferred choice for fully aqueous workflows or delicate proteins that cannot tolerate organic solvent.
-
Phenothiazines, ROS, and Autophagy in Macrophages
2026-09-29
A 2025 Frontiers in Immunology study shows that phenothiazines strengthen macrophage antibacterial activity by increasing reactive oxygen species, lysosomal function, and autophagy. Perphenazine also reduced tissue lesions and inflammation in a Salmonella Typhimurium infection model, supporting phenothiazines as host-directed lead compounds while leaving receptor specificity, dosing, and clinical translation unresolved.
-
Rotigotine Nose-to-Brain Delivery in PD Models
2026-09-29
Bhattamisra and colleagues developed rotigotine-loaded chitosan nanoparticles for intranasal nose-to-brain delivery and evaluated them in SH-SY5Y cells and a haloperidol-induced rat model. The formulation showed cellular compatibility, altered neurotoxicity-related biomarkers, improved motor outcomes, and increased brain-targeting efficiency, while the study also highlights important limits of acute models for Parkinson’s disease translation.
-
Z-YVAD-FMK Workflows for Caspase-1 Assays
2026-09-28
Use Z-YVAD-FMK to test whether caspase-1 contributes to inflammatory signaling and cell death—not as a stand-in for a general apoptosis inhibitor. This workflow pairs a practical dose-finding plan with controls that help distinguish caspase-1-dependent responses from bystander necroptosis.
-
SCH772984 HCl: ERK1/2 Inhibitor Workflows
2026-09-27
Use SCH772984 HCl to test whether ERK1/2 activity sustains MAPK output, tumor-cell growth, or TERT expression. This practical guide connects cancer-model workflows with a recent human stem-cell study while keeping its findings distinct from proposed experiments.
-
HyperScript™ Reverse Transcriptase in Fusion-RNA Assays
2026-09-26
HyperScript™ Reverse Transcriptase can support RNA-to-cDNA conversion when fusion transcripts are structured or scarce. This article connects enzyme choice to assay design and interpretation in FGFR2 fusion research, while distinguishing measurement quality from therapeutic evidence.
-
Phosphatase Inhibitor Cocktail 3 for YAP Studies
2026-09-26
Preserve phosphorylation during lysis when investigating Hippo–YAP signaling, RNF166, and angiomotins. This practical guide shows how Phosphatase Inhibitor Cocktail 3 can support phosphoprotein analysis while keeping phosphatase inhibition distinct from the PARylation mechanism at the center of the colorectal cancer study.
-
Hoechst 33342/PI Double Staining Kit: Practical Guide
2026-09-25
The Hoechst 33342/PI Double Staining Kit provides a fluorescence-based way to assess nuclear chromatin appearance alongside cell membrane integrity, helping researchers distinguish staining patterns associated with viable, apoptotic, and membrane-compromised cells. It is for laboratory research, not diagnosis or medical use; stain volumes, incubation conditions, and instrument settings should be established from the current kit instructions and validated for the sample type.